Laboratorio de Lípidos y Aterosclerosis, Departamento de Bioquímica Clínica, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires 1113, Argentina.
Facultad de Farmacia y Bioquímica, Instituto de Fisiopatología y Bioquímica Clínica (INFIBIOC), Universidad de Buenos Aires, Buenos Aires 1113, Argentina.
Cells. 2019 Feb 14;8(2):158. doi: 10.3390/cells8020158.
Extracellular matrix (ECM) remodeling is required for many physiological and pathological processes. Metalloproteinases (MMPs) are endopeptidases which are able to degrade different components of the ECM and nucleus matrix and to cleave numerous non-ECM proteins. Among pathological processes, MMPs are involved in adipose tissue expansion, liver fibrosis, and atherosclerotic plaque development and vulnerability. The expression and the activity of these enzymes are regulated by different hormones and growth factors, such as insulin, leptin, and adiponectin. The controversial results reported up to this moment regarding MMPs behavior in ECM biology could be consequence of the different expression patterns among species and the stage of the studied pathology. The aim of the present review was to update the knowledge of the role of MMPs and its inhibitors in ECM remodeling in high incidence pathologies such as obesity, liver fibrosis, and cardiovascular disease.
细胞外基质(ECM)的重塑是许多生理和病理过程所必需的。金属蛋白酶(MMPs)是内肽酶,能够降解 ECM 和核基质的不同成分,并切割许多非 ECM 蛋白。在病理过程中,MMPs 参与脂肪组织扩张、肝纤维化、动脉粥样硬化斑块的发展和易损性。这些酶的表达和活性受不同激素和生长因子的调节,如胰岛素、瘦素和脂联素。到目前为止,关于 MMP 在 ECM 生物学中的行为的有争议的结果可能是由于物种之间的不同表达模式和所研究病理阶段的不同。本综述的目的是更新关于 MMP 及其抑制剂在肥胖、肝纤维化和心血管疾病等高发疾病中 ECM 重塑中的作用的知识。